Raymond James Financial
NPCE icon

Raymond James Financial’s Neuropace NPCE Stock Holding History

Raymond James Financial’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,105
Closed -$12.3K – 6119
2025
Q2 		$12.3K Buy
+1,105
New +$13.8K ﹤0.01% 5832

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Raymond James Financial's NPCE Position: Q3 2025 in Review

Raymond James Financial sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 1,105 shares — an estimated $12.3K sold.

Raymond James Financial first reported a position in NPCE in Q2 2025 and held it in 1 quarter. The position peaked at $12.3K in Q2 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Raymond James Financial reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 1,105 Neuropace shares in Q3 2025, an estimated $12.3K.
  • Raymond James Financial first reported a position in Neuropace in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Neuropace position peaked at $12.3K in Q2 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.